Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Genitourinary 1

Conditions

Multiple Myeloma 4Neoplasms 2Lymphoma 2Leukemia 2Recurrence 1Prostatic Neoplasms 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Liposarcoma 1

Interventions

Gemcitabine 57Paclitaxel 50Cyclophosphamide 45pembrolizumab 44Carboplatin 41Bevacizumab 38Cisplatin 33Docetaxel 31Fluorouracil 30Nivolumab 29Capecitabine 29Pemetrexed 24Irinotecan 24Oxaliplatin 23Dexamethasone 23Ipilimumab 22Leucovorin 21Radiotherapy 20Sorafenib 19Doxorubicin 19Everolimus 18Cetuximab 18fludarabine 17Albumin-Bound Paclitaxel 17trametinib 15Sunitinib 15Rituximab 15Erlotinib Hydrochloride 15130-nm albumin-bound paclitaxel 15Prednisone 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Neoplasms × plitidepsin × Clear all
NCT00780975 2020-11-24

A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer

PharmaMar

Phase 2 Terminated
8 enrolled 9 charts
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT00780143 2018-11-09

Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia

PharmaMar

Phase 1/2 Terminated
3 enrolled 6 charts
Other hematologic neoplasm

Leukemia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡